Related Experiment Videos
[Effects of indenolol on left ventricular mass in patients with essential arterial hypertension]
Insights
Long-term indenolol therapy effectively lowered blood pressure and reduced cardiac output in hypertensive patients. This beta-blocker also reversed left ventricular hypertrophy without affecting systolic function.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Hypertension is a major risk factor for cardiovascular disease, often leading to left ventricular (LV) hypertrophy.
- Long-term antihypertensive therapy is crucial for managing hypertension and preventing cardiac complications.
Purpose:
- To evaluate the long-term efficacy and hemodynamic mechanisms of indenolol, a beta-blocker with beta-2 stimulating activity, in treating hypertensive patients.
- To assess the impact of indenolol on hypertensive left ventricular hypertrophy.
Summary:
- Fourteen hypertensive patients received 12-month therapy with indenolol (60-120 mg daily).
- Significant reductions in blood pressure, heart rate, and cardiac output were observed after one month.
- Left ventricular posterior wall thickness, interventricular septum thickness, and LV mass decreased significantly after six and twelve months, respectively.
- Blood pressure normalized in 50% of patients, and LV mass normalized in 40%.
Impact:
- Indenolol demonstrates effectiveness as a long-term antihypertensive agent.
- The drug's antihypertensive effect is primarily attributed to a reduction in cardiac output.
- Indenolol successfully regressed left ventricular hypertrophy in hypertensive patients without compromising LV systolic function.
Abstract:
This study evaluated the effect of long-term antihypertensive therapy with indenolol, a beta blocking agent with beta 2 stimulating activity, its antihypertensive hemodynamic mechanism and its effect on hypertensive left ventricular (LV) hypertrophy. Fourteen hypertensive patients, mean age of 48 years, were serially studied during 12- month therapy with indenolol (60-120 mg daily), by recording blood pressure, electrocardiogram and echocardiogram. Blood pressure, heart rate and cardiac output significantly decreased after 1 months of therapy, LV posterior wall thickness decreased after 6 months, interventricular septum thickness and LV mass decreased after 12 months. LV fractional shortening did not change throughout the study. Blood pressure normalized (less than or equal to 140/90 mmHg) in 50% of the patients; LV mass normalized in 40% of the patients. In conclusion, indenolol was an effective antihypertensive agent, also in the long-term treatment. Its antihypertensive hemodynamic effect seems to be due mainly to a reduction in cardiac output. Indenolol caused a regression of LV hypertensive hypertrophy without impairment of LV systolic function.